DEF: Biofrontera Inc. Seeks Stockholder Approval for Share Increase and Director Election at 2025 Annual Meeting

Biofrontera Inc. is holding its 2025 Annual Meeting of Stockholders virtually on June 12, 2025, to vote on key proposals including a share increase and director election.

Summary

• Biofrontera Inc. will hold its 2025 Annual Meeting of Stockholders on June 12, 2025, in a virtual format.
• Stockholders will vote on the election of one Class I director, an amendment to increase the authorized shares of common stock from 35,000,000 to 70,000,000, a proposal to adjourn the meeting if necessary, and the ratification of CBIZ CPAs P.C. as the independent registered public accounting firm for the year ending December 31, 2025.
• The Board of Directors recommends voting FOR the election of Dr. Heikki Lanckriet as Class I director and FOR the ratification of CBIZ CPAs P.C.
• As of the record date, April 22, 2025, there were 9,446,197 shares of Common Stock and 9,724 shares of Preferred Stock outstanding, representing 9,446,197 and 499,468 votes respectively.
• The company is distributing proxy materials online to expedite delivery and reduce costs.
• The Board of Directors believes increasing the authorized shares of Common Stock is in the best interest of the company and its stockholders.
• The company entered into a securities purchase agreement in November 2024 for $4.2 million in convertible notes, which may require the issuance of up to 5,384,615 shares of Common Stock upon conversion.
• The company may appoint up to two additional directors to its Board of Directors, each of whom shall be designated by one of the investors, pursuant to securities purchase agreements entered into in February 2024.

Sentiment

Score: 6

Explanation: The document is primarily informational, outlining standard corporate governance procedures. The sentiment is neutral, with a slight positive leaning due to the company's efforts to secure its future financial flexibility.

Positives

• The company is taking steps to ensure it has sufficient authorized shares for future needs, including potential financing activities and equity incentives.
• The company is using a lower cost, more environmentally responsible method by distributing proxy materials online.
• The Board of Directors is actively engaged in risk oversight through its committees.
• The company has a compensation recovery (clawback) policy in place.

Negatives

• The company's auditor resigned in 2023 and again in 2025, requiring the appointment of a new auditor.
• The company's convertible notes offering could lead to significant dilution if the notes are converted into common stock.
• The company's success depends in part on its continued ability to attract, retain and motivate highly qualified management and clinical personnel, and if the Share Increase Proposal is not approved by our stockholders, the lack of unissued and unreserved authorized shares of Common Stock to provide future equity incentive opportunities that the Compensation Committee of the Board deems appropriate could adversely impact our ability to achieve these goals.

Risks

• Failure to approve the Share Increase Proposal could limit the company's ability to raise future capital and pursue strategic opportunities.
• Future issuances of Common Stock could have a dilutive effect on earnings per share, book value per share, and the voting power of current stockholders.
• The availability of additional authorized shares could discourage or make more difficult efforts to obtain control of the company.
• The company faces risks related to its financial condition, development and commercialization activities, operations, strategic direction, and intellectual property.

Future Outlook

The company aims to have sufficient shares available for future corporate purposes, including financing activities, stock dividends, conversions of convertible securities, equity awards, strategic relationships, and acquisition transactions.

Management Comments

• The Board of Directors has determined that combining the roles of Chairman and Chief Executive Officer is the best leadership structure for the Company at this time because of Prof. Luebberts experience with the Companys business and industry, as well as his ability to effectively identify strategic priorities of the Company and facilitate execution of the Companys strategy.

Industry Context

The document does not provide specific details on how this announcement relates to broader industry trends or competitors.

Related Party Transactions

• The company relies on the Biofrontera Group as the sole supplier of Ameluz and the RhodoLED Lamps.
• The company entered into the Second Amended and Restated License and Supply Agreement with Biofrontera Pharma and Biofrontera Bioscience, effective as of February 13, 2024.
• The company entered into an Amended and Restated Master Contract Services Agreement with Biofrontera AG, Biofrontera Pharma and Biofrontera Bioscience in December 2021.
• The company executed a clinical lamp lease agreement with Biofrontera Bioscience on August 1, 2018.

Stakeholder Impact

• Approval of the Share Increase Proposal could impact shareholders through potential dilution.
• The election of directors will determine the leadership and strategic direction of the company.
• The ratification of the auditor ensures the integrity of the company's financial reporting.

Next Steps

• Stockholders to vote on the proposals at the Annual Meeting on June 12, 2025.
• The company will file a Certificate of Amendment to the Certificate of Incorporation if the Share Increase Proposal is approved.
• The company will announce preliminary voting results at the Meeting and publish final results in a Current Report on Form 8-K.

Key Dates

Keywords

proxy statement, annual meeting, share increase, director election, CBIZ CPAs, common stock, preferred stock, convertible notes, Biofrontera